Bridging the deficit: Assessing knowledge gaps in thyroid cancer management amongst physicians in the Democratic Republic of Congo

doi:10.5306/wjco.v16.i7.107495

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (665)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-3) series.

Item

Count

PDF

HTML

421

Tables (1-3)

125

Sum=571

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=59

Jul 24, 2025 (publication date) through Aug 31, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Clin Oncol. Jul 24, 2025; 16(7): 107495
Published online Jul 24, 2025. doi: 10.5306/wjco.v16.i7.107495

Table 1 Respondents’ knowledge of thyroid cancer, n (%)

Question	Correct answer	Incorrect answer	Total
Most affected gender by thyroid cancer	273 (74)	96 (26)	369
Age group most at risk for developing thyroid cancer	194 (52.6)	175 (47.4)	369
Most common type of thyroid cancer	149 (40.4)	220 (59.6)	369
Risk factors for thyroid cancer	122 (33.1)	247 (66.9)	369
Most common treatment for thyroid cancer	189 (51.2)	180 (48.8)	369
Type of thyroid cancer associated with multiple endocrine neoplasia	162 (43.9)	207 (56.1)	369
Most aggressive type of thyroid cancer	167 (45.3)	202 (54.7)	369
Most common symptom of thyroid cancer	244 (66.1)	125 (33.9)	369
Factors involved in the etiology of thyroid cancer	189 (51.2)	180 (48.8)	369
Familial forms associated with medullary thyroid cancer	150 (40.7)	219 (57.3)	369
Risk posed by elevated TSH levels in the context of a thyroid nodule	179 (48.5)	190 (51.5)	369
Thyroid cancer associated with the use of GLP-1 analogs	109 (29.5)	260 (70.5)	369
Factor most associated with thyroid cancer in patients with a thyroid nodule	160 (43.4)	209 (56.6)	369
Link between iodine deficiency and thyroid cancer	222 (60.2)	147 (39.8)	369
Tumor suppressor gene P53 mutation and thyroid autoimmunity	1 (0.3)	368 (99.7)	369
Thyroid cancer and receptor mutations	91 (24.7)	278 (75.3)	369
Genetic mutations in differentiated thyroid cancers compared to anaplastic type	259 (70.2)	110 (29.8)	369
Histological type of thyroid cancer with the highest recurrence rate	78 (21.1)	291 (78.9)	369
Factors associated with an increased risk of recurrence in thyroid cancer patients	153 (41.5)	216 (58.5)	369
Organ most commonly affected by distant metastases in thyroid cancer	154 (41.7)	215 (58.3)	369
Factors associated with poor prognosis in thyroid cancer patients	35 (9.5)	334 (90.5)	369
Most common cause of death in thyroid cancer patients	107 (31.1)	262 (68.9)	369

TSH: Thyroid-stimulating hormone; GLP-1: Glucagon-like peptide-1.

Citation: Bukasa-Kakamba J, Bangolo AI, Poka N, Bompongo C, Wadhwani S, Wadhwani N, Kalambayi IK, Mutombo MB, Fwelo P, Bayauli P, Menga G, Sifa A, Diazabakana C, Kingebeni G, Mulumba M, Mambu D, Bokondo RM, M’Buyamba-Kabangu JR. Bridging the deficit: Assessing knowledge gaps in thyroid cancer management amongst physicians in the Democratic Republic of Congo. World J Clin Oncol 2025; 16(7): 107495
URL: https://www.wjgnet.com/2218-4333/full/v16/i7/107495.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i7.107495